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Allergies are a pervasive issue and require novel ways of alleviating symptoms.
Existing treatments focus on symptom management and immunotherapy in response to
an allergic reaction. However, there is also the potential for prophylactic treatment that
inhibits molecules involved in the mast cell degranulation pathway, which causes allergic
symptoms. We identified potential target proteins downstream of this pathway including
PKC, PLCγ, and PI3K isoforms, the activation of which results in the degranulation of
mast cells. We computationally modeled protein-inhibitor binding interactions and
identified inhibitors with the predicted highest binding affinity to the target pathway
proteins. For the most efficient inhibitors, we extended our analysis by construction of
analogs to determine which chemical properties of the inhibitors contributed to the
highest binding affinity. The identified possible inhibitors have the potential to hinder
mast cell degranulation, limit histamine and cytokine release, and therefore prevent
allergic symptoms, making them ideal targets for future pharmacology research.
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An allergy is a chronic condition due to an adverse reaction to an otherwise
harmless environmental substance within the immune system. Allergies impede both the
dietary and social lives of those affected as well as the families and communities
surrounding each person. The allergic response is characterized by a range of symptoms
from sneezing, runny nose, coughing, and itching to life-threatening reactions such as
anaphylactic shock (Centers for Disease Control and Prevention, 2017). According to the
World Health Organization (2011), the percentage of persons with sensitivity to allergens
is 40% and climbing; it is the most pervasive disorder globally. In the United States,
allergies are the sixth leading cause of chronic illness (Centers for Disease Control and
Prevention, 2017).
Generally, allergies are the product of repeated reactions within the immune
system to a specific allergen. In every reaction, the immune cells known as mast cells are
activated, triggering a cascade of molecules to bind, activate, or recruit each other in a
complex signaling pathway. This leads to degranulation, a process in which the cells
release cytotoxic molecules and other inflammatory mediator molecules resulting in the
manifestation of allergic reactions.  (Metcalfe et al., 2009). Currently, the most common
therapeutics can be characterized in three ways: avoidance of the allergen, medication to
treat symptoms, and immunotherapy. These current therapeutics involve significant
lifestyle changes and treatment upkeep for the patients. Additionally, although
inexpensive treatments are available, many patients find them insufficient for symptom
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management. Therefore, there exists the opportunity to research novel allergy therapeutic
options.
This research focuses on the intracellular signaling pathway within mast cells to
screen for novel drug targets and identify inhibitors with the best binding affinity to
signaling proteins. Previous treatments have targeted extracellular binding of antibodies
and downstream release of inflammatory molecules, but not the signaling pathway. The
identified inhibitors could then be synthesized by pharmaceutical companies and this
allergy medication could be taken prophylactically.
To determine which inhibitors had the lowest binding energies, signaling protein
structures were modeled in Phyre2 and refined using Modrefiner; these 3D structures
were then modeled with different known inhibitors using PyRx, which outputted binding
energies. The inhibitors that demonstrated protein-inhibitor interactions with the lowest
binding energies were selected, and analogues of these inhibitors were derived from the
ZINC database and modeled against signaling molecules. This analysis demonstrates
proof of concept of the modeling procedure to identify effective inhibitors against
biological signaling molecules, which can be refined and utilized in future drug screening
procedures.
There are a few limitations to this study. These include the use of in silico
modeling, which cannot entirely simulate the conditions in the human body. There might
be unintentional effects on other biological processes due to the ubiquity of the target
proteins in the human body. Furthermore, the modeling software is giving a best
estimation of the binding energies, but these values are not exact, and may also differ
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when done in vitro and in vivo. Therefore, further experimentation should be done in
mast cell lines and murine models to verify these findings.
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Literature Review
This section provides an overview of published works on the basic functions of
the immune system, key components of the allergic response from the binding of
antibodies to mast cells to the signaling pathway leading to degranulation, current
treatments for allergic disease, and potential drug targets.
Overview of Immune Responses
In an adaptive immune response, the body utilizes many cell types to combat
foreign substances known as antigens. When an antigen enters the body, it is detected and
phagocytized by antigen-presenting cells (APCs). The engulfed antigen is broken up into
peptide fragments by acid hydrolases in phagolysosomes which are then presented on
surface proteins on the exterior of the APC (Warrington et al., 2011). These surface
proteins, known as the major histocompatibility complex 2 (MHC2), work in conjunction
with a second signal known as co-stimulation in order to induce T cell maturation and
differentiation (Bonilla & Oettgen, 2010). If the T cell matures into a helper T cell, it can
use the specificity of the original antigen to prompt B cells into producing
antigen-specific antibodies. In different pathways, the B cell acts as an APC itself, and
can use the antigen fragments to make specific antibodies (Bonilla & Oettgen, 2010).
This is the mechanism of antibody-mediated immunity.
Due to DNA rearrangements within the B cell, every antibody made by a specific
B cell is unique to that antigen and to its B cell (Alberts et al., 2002). This allows the B
cells to make many antibodies to combat a specific antigen. After the encounter of an
antigen, the B cell can clonally expand and differentiate into antibody-secreting effector
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cells. Other B cells do not become effector cells, but function to retain the genetic
memory for producing that specific antibody in order to ensure that a second exposure
will trigger a more effective attack on the foreign substance (Warrington et al., 2011).
Most commonly in a normal immune response, effector B cells produce the
immunoglobulin G (IgG) antibodies. Once bound to their specific antigen, the antibody
can enact the antibody-mediated immune response, also known as the humoral immune
response. Antibodies coat the antigen, which can block many of the pathogenic
mechanisms of an antigen such as adhering to host tissues or binding to other mechanistic
structures needed to carry out infection (Forthal, 2014). In other cases, opsonization
occurs when the antibody coating of antigens promotes phagocytosis (Janeway et al.,
2001). The presence of antibodies coating the antigens can cause phagocytes of the
immune system to recognize protein sequences within the Fc region of the IgG antibodies
and bind to Fcγ receptors found on the surface of the phagocytes (Hiemstra & Daha,
1998). This binding increases phagocytosis by pulling the membrane of the phagocyte
around the antigen (Hiemstra & Daha, 1998). A final aspect of the humoral response
occurs in the form of complement activation, which can lead either to enhanced
opsonization or pathogen cell lysis (Noris & Remuzzi, 2013). In summary, the normal
humoral immune response is largely dictated by the activity of immunoglobulin G and
results in the neutralization of pathogenic substances to the body. This greatly differs
from the allergic response, which is dictated by IgE rather than IgG.
6
Allergic Response Mechanism
In the allergic response mechanism, the naive T helper cell recognizes the antigen
and the co-stimulatory molecule, it becomes a mature T Helper 2 cell (TH2). When
interacting with the B cell, cytokines such as Il-4, Il-5, and Il-13 trigger the B cell to start
producing Immunoglobulin E (IgE) instead of IgG (Bubnoff et al., 2001). The IgE then
binds to the FcεR1 receptor on the mast cell. If there is another exposure of this same
antigen, the specific IgE antibody is already produced and bound to the mast cell
(Warrington et al., 2011). Once it recognizes the antigen, the Fab region of the IgE binds
to the antigen. This causes the mast cell to degranulate and release proinflammatory
mediators such as histamines, prostaglandins, and leukotrienes (Galli et al., 2008).
Depending on the proinflammatory mediator released, the body expresses different
reactions, as shown in Figure 1.
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Figure 1. The mechanism of IgE mediated allergic reaction. (Nagai,, Teramachi,
& Tuchiya 2006)
Many proinflammatory mediators have overlapping effects, which can cause
symptoms such as coughing, sneezing, wheezing, hives, mucus secretion, and
anaphylaxis. In most cases, these symptoms are a result of acute inflammation in which
the body is working to heal itself and are temporary (Galli et al., 2008). Allergic diseases
such as eczema, hay fever, sinusitis, and asthma, however, are the result of chronic
inflammation (Galli et al., 2008). The specific mechanisms leading to this kind of chronic
inflammation are still not completely understood.
One of the major proinflammatory mediators released are histamines, which bind
to H1 receptors and cause the smooth muscles of the bronchi to contract (Faustino-Rocha
et al., 2017). This makes breathing difficult as the airways start to close. In addition,
histamines cause blood vessel dilation and increase permeability of the blood vessel
walls. In severe cases of allergic responses, rapid onset of histamine release can cause a
combined attack of oral, skin, respiratory, cardiovascular, gastrointestinal, and neurologic
systems known as anaphylactic shock, which can be life-threatening (Kim & Fischer,
2011).
Prostaglandins are important in both early and late immune responses. They can
also cause the smooth muscle to contract, causing coughing, wheezing, and shortness of
breath (Satoh et al., 2006). Persistent bronchial hyperreactivity can lead to the diagnosis
of asthma. Six hours after the exposure to the allergen, it is also involved in the
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pathogenesis of urticaria, allergic rhinitis, and allergic bronchial asthma (Satoh et al.,
2006).
Leukotrienes are seen to have a role in many chronic inflammatory diseases (Liu
& Yokomizo, 2015). For example, they are correlated with eczema, asthma, and hay
fever. The molecules are also related to some more acute symptoms such as
bronchoconstriction, mucus secretion, and anaphylaxis.
Immunoglobulin G and Immunoglobulin E
Human immunoglobulin (Ig) is a Y-shaped protein produced by plasma cells to
aid the immune system in destroying foreign bacteria (Schroeder & Cavacini, 2010). Of
the five antibody classes, IgG and IgE are the two isotypes directly involved in allergy
mechanisms (Warrington et al., 2011). All immunoglobulin are composed of two heavy
(H) and two light (L) chains, and a combination of variable (V) and constant (C) regions.
The light chains are made up of one V region and one C region. The heavy chains are
made up of one V region and three C regions (Schroeder & Cavacini, 2010). The variable
regions of the heavy and light chain are paired together at the top of the antibody to
create an antigen binding site. The constant regions specify effector functions, such as
binding to the Fc regions of mast cells, and determine the specific isotype of the
immunoglobulin (Schroeder & Cavacini, 2010).
Immunoglobulin G (IgG) is the most abundant immunoglobulin within the blood
and lymph nodes. IgG has a large role in the opsonization of pathogens (Warrington et
al., 2011). IgG also engages in agglutination in which the antibody can connect multiple
antigen particles in order to create large clumps for easier and more efficient recognition
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and degradation (Warrington et al., 2011). Finally, IgG is the only immunoglobulin that
can pass through the placenta. This is very important because mothers can pass their IgG
into their offspring, therefore passing certain immunities onto their offspring (Warrington
et al., 2011).
Immunoglobulin E (IgE) is the antibody most directly related to allergies (Stone
et al., 2010). When the immune system produces an allergic mechanism, the B cells
switch from producing IgG to producing IgE. IgE binds to the FcεR1 receptor on mast
cells in order to induce an immune response to a foreign substance. Once the IgE is
bound to the Fc portion of the FcεR1 receptor, it can capture antigens, causing the mast
cell to release its granules which contain proinflammatory mediators (Galli et al., 2008).
B Cell Activation
In the immune response, naive B cells undergo a process known as class switch
recombination in which the class of antibody is changed from IgM to either IgG, IgE, or
IgA by means of a chromosomal deletion along the locus for the antibody’s heavy chain
(Stavnezer et al., 2008). There are two main components to class switching in
T-dependent B cell activation. The first component is the binding of the CD40L molecule
on a T cell with the B-cell surface receptor CD40, and the second is the release of
cytokines by that T cell (Maddaly et al., 2010). Once the B cell is activated, enzyme
activation induced cytidine deaminase (AID) oversees the deletion along two splice sites
known as switch (S) regions (He et al., 2015). The first S region is fixed just upstream of
the coding sequences for IgM and IgD (Stavnezer et al., 2008). The second S region to be
cut is determined by cytokines produced by helper T cells. Cytokine interferon-γ (IFN-γ)
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causes a splice site just before the gene sequence for IgG to be cut, excising the sequence
for IgM and IgD (Kawano et al., 1995). Cytokine interleukin 4 (IL-4) is responsible for
the deletion resulting in the generation of IgE antibodies (Stavnezer & Schrader, 2014).
Thus, the specific isotype of antibody produced by a B cell is dependent on the cytokines
produced by the helper T cell.
FcεR1
FcεRI is expressed on mast cells and basophils and has a high affinity for IgE
(Metz et al., 2008). Structurally, FcεR1 is tetrameric and is composed of, an α, β, and 2
disulfide-linked γ subunits. The β and γ chains are involved in signal transduction after
binding of IgE in order to mediate the cell’s response to IgE binding, and dictate
subsequent signal cascades and histamine release. The FcεR1 receptor is present in its
complete form and expressed at a constitutive level only on basophils and mast cells
(Metz et al., 2008). However, it is also present in a reduced form α𝛾2, in which the β
signaling subunit is not present, in cells like dendritic cells, eosinophils, and platelets. IgE
binding to FcεR1 causes its upregulation.
Signaling Pathways
The binding of IgE to FcεR1 on mast cells and basophils results in a cascading
web of signaling pathways between a complex array of adaptor proteins, kinases, and
other molecules. These events lead to two events specific to the allergic mechanism
symptom manifestation: mast cell degranulation and cytokine production, as depicted in
Figure 2.
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Figure 2: Overview of cell signaling pathways within mast cells. (Gilfillan, & Tkaczyk
2006)
Lipid Rafts, LYN, FYN, GAB2, PI3K
In the early part of the signaling pathway, IgE-antigen complexes bind to the
FcεR1 receptor (Oettgen & Burton, 2015). Before this binding, FcεR1 receptors have a
low affinity to insert into lipid rafts, regions of the cell membrane where certain
glycolipids cluster to form microdomains useful in signaling (Dykstra et al., 2003). After
IgE-antigen binds to FcεR1, however, oligomeric antigens cross-link IgE bound to FcεR1
just long enough to assemble a “signalosome” made of adaptor proteins and other
signaling proteins that promote raft clustering and bind to the actin cytoskeleton to
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stabilize the receptors in the lipid raft (Dykstra et al., 2003). Then, tyrosines in
immunoreceptor tyrosine-based activation motif (ITAM) sequences, found in the
cytosolic domains of the FεcR1 β and γ chains, become phosphorylated by Src kinase
Lyn (Metcalfe et al., 2009). Lyn kinase is preferentially found in these membrane
microdomains and shifts the equilibrium from most inactive to mostly phosphorylated
and active FcεR1 (Gilfillan & Tkaczyk, 2006).
Figure 3. Process of creating lipid raft with IgE-antigen and FcεR1 oligomers
(Dykstra et al., 2003)
Fyn kinase is also found in these lipid rafts and binds more tightly to the β subunit
of FεcR1 when the receptor is activated (Parravicini et al., 2002). It is responsible for
phosphorylating GRB2-associated binding protein 2 (Gab2). Gab2, like its analogs of
Gab1 and Dos, is a scaffold adaptor protein that signal molecules can bind to. Gab-/-
mice were found to have both impaired mast cell degranulation and cytokine expression
(Gu et al., 2001). Phosphorylation of Gab2 causes a conformational change to recruit
molecules like Src-homology domain 2-containing protein tyrosine phosphatase 2
(SHP2) and phosphatidylinositol-3-OH kinase (Ptdlns-3K or PI3K).
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PI3K is a family of lipid kinases known to be involved in many cellular functions
such as cell growth, development, proliferation, and survival (Hemmings & Restuccia,
2012). They are involved in pathways leading to endocytosis, vesicle trafficking,
autophagy, signaling, cortical remodeling, secretion, and cytokinesis. Deregulation of
PI3K can lead to tumorigenesis (Jean & Kiger, 2014). Here we will focus on the
immediate involvement of PI3K within the pathway previously described as activated by
Gab2.
In the mast cell degranulation signaling pathway, PI3K is activated by the adaptor
molecule Gab2. When recruited, the regulatory subunit of PI3K in conjunction with a
tyrosyl phosphorylated SHP binds to sites on Gab2 (Gu et al., 2001). Once bound, class
1A PI3K containing p85 and p110 subunits convert the membrane lipid
phosphatidylinositol-(4,5)-bisphosphate (PIP₂) to
phosphatidylinositol-(3,4,5)-trisphosphate (PIP₃) (Kim et al., 2008). PIP₃ has docking
sites that are made available to associating proteins at domains called
pleckstrin-homology domains (Gilfillan & Tkaczyk, 2006). Some associating proteins
called to PIP₃ include PLCγ, VAV, PLD, SK, and BTK.
There are two well established inhibitors of PI3K: wortmannin and LY294002.
Wortmannin is a fungal toxin which binds to the p110 subunit of PI3K (Barker et al.,
1995). Wortmannin has been  shown to reduce levels of degranulation when tested in the
rat basophil leukemia cell line RBL-2H3 (Gilfillan & Tkaczyk, 2006). The second
inhibitor of PI3K is known as LY294002. LY294002 is a more stable alternative to
wortmannin in solution with a tradeoff of requiring a much higher concentration in order
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to reach the same level of inhibition (Walker et al., 2000). Other inhibitors such as
quercetin, myricetin, and staurosporine have also been tested as PI3K inhibitors,
providing proof of concept for allergic therapy in the inhibition of PI3K (Walker et al.,
2000).
PLCγ and PLD Pathways
Syk tyrosine kinase activates adaptor molecules that lead to the activation of
phospholipase Cγ (PLCγ), a critical molecule for B cell activation (Peng & Beaven,
2005). There are two forms of PLCγ with PLCγ-1 mainly expressed in mast cells and T
cells and PLCγ-2 mainly involved in B-cells (Kim, 2000). PLCγ is the signaling enzyme
that catalyzes the hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2), a
phosphoinositide on the plasma membrane, into the second messengers DAG and inositol
1,4,5-trisphosphate (IP₃) (Kim, 2000). These two cleavage products have important and
independent roles in subsequent signaling that ultimately results in calcium release and
PKC activation (Gericke, 2013). PLC inhibitor U-73122 has been previously tested in
inhibiting PI hydrolysis and IP₃ synthesis in neutrophils, neuroblastoma cells, and
platelets, and has been cited as a possible inhibitor of PLC (MacMillan & JG McCarron,
2010).
IP₃ production induces calcium release in the endoplasmic reticulum, that in turns
causes calcium to flow in from extracellular channels (Rivera & Gilfillan, 2006). This
influx of calcium leads to steps initiating transcription and differentiation. Internal
calcium is also involved in a number of other activating processes, such as in the
activation of Protein Kinase C (PKC).
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PKC is a group of lipid dependent kinases that phosphorylate protein structures
and serve as effector molecules (Becker, 2005). DAG generation recruits PKC to migrate
to the plasma membrane, during the path in which it attaches to and activates PLD
(Becker, 2005). DAG competes with phorbol esters to bind to the C1 site on PKC
(Becker, 2005). This could possibly become an area of interest for cascade inhibition.
There are several different subgroups of PKC, some of which are dependent on DAG and
calcium, some DAG alone, and some on neither (Singer et al., 1996). Of the calcium
dependent groups, DAG generally binds to the C1 unit and calcium to the C2 unit, while
in the calcium-independent groups, only DAG binds to the C1 unit (Huang 1989). PKC
inhibitors such as staturosphine and calphostin C have been seen to block PLD activation.
However, there are some studies that suggest that calphostin may act directly upon PLD
(Peng & Beaven, 2005).
Production of DAG is what triggers PKC to bind and interact with PLD, though
this pathway is less understood. It has direct contact with kinases such as Protein Kinase
C (PKC), ERK, and Tyrosine Kinase 2 (TYK). DAG is produced by PLC, which then
induces PLD to produce its own DAG in a much greater amount in order to activate PKC
(Peng & Beaven, 2005). Activation of PLD has been linked to the production of
phosphatidic acid (PA), diacylglycerol (DAG), and choline. PA itself also targets and
regulates PKC (Peng & Beaven, 2005).
Sphingosine Kinase Pathway
Sphingosine kinase (SphK) is another enzyme found in the mast cell pathway.
The role of SphK is to catalyze the phosphorylation of sphingosine to form
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sphingosine-1-phosphate (S1P) (Sun & Bonder, 2012). S1P is known to have a role in the
signaling processes of various diseases from cancers, to diabetes, osteoporosis, and
allergies and asthma (Maceyka et al., 2011). In the allergic response, SphK and S1P are
involved in survival, differentiation, migration, and activation (Sun & Bonder, 2012).
There are two isoenzymes which form S1P, the SphK1 and the SphK2. These
enzymes catalyze the phosphorylation of sphingosine to form S1P. SphK1 regulates cell
growth and survival, but when overexpressed SphK2 induces cell death (Olivera et al.,
1999). Both SphK1 and SphK2 were found to have increased activity when the FcεRI
receptor was activated in mast cells (Mizugishi et al., 2005).
S1P has two receptors, S1P1 and S1P2, which are both expressed on the surface of
mast cells. (Oskeritzian et al., 2007). S1P1 regulates migration of mast cells towards
antigens. S1P2 is known to mediate mast cell activation and degranulation, which makes
it a better target for this research. (Oskeritzian et al., 2007). The S1P that is secreted by
the mast cell is able to bind to these receptors.
PKA and cAMP
Protein kinase A (PKA) is an enzyme that phosphorylates other proteins to
regulate their function. Its two catalytic subunits are responsible for the phosphorylation
activity, while its two regulatory subunits are able to detect and properly react to levels of
cyclic AMP (cAMP). When cAMP levels are low, the catalytic subunit is inactive, and
when cAMP levels are high, the catalytic subunit is active. Research suggests that
administering a treatment using an antagonist of cAMP or shRNA down-regulation of
PKA reversed the EP2-mediated inhibitory effect on MC degranulation (Serra-Pages,
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Olivera, Torres, Picado, de Mora, & Rivera, 2012). A molecule called PGE2 can mediate
the suppression of mast cell degranulation, which researchers found could be modulated
to vary from activating to suppressing, depending on the relative ratio of EP2 to EP3 (two
types of G protein coupled receptors) expression on these cells with suppression evident
only in cells having increased EP2 to EP3 expression. (Serra-Pages et al., 2012).
Current Treatments
Symptom Management
Currently, there is no cure for allergies. Relatively common and established
treatment recommendations for allergies are focused on avoidance measures and
pharmacotherapy-based symptom management (Lanser et al., 2015). Although the
recommendation of avoiding allergens will certainly lessen allergen exposure and thus
the subsequent allergic response, the measure is impractical and inconvenient in daily
practice (Marple et al., 2007).
Some treatments, such as decongestants and corticosteroids, focus on treating the
symptoms of allergies. Decongestants relieve the nasal congestion associated with
allergies by reducing swelling in nasal tissues and blood vessels (AAAAI, 2018).
Corticosteroids also work to reduce inflammation in addition to ameliorating stuffiness,
sneezing, and runny nose. There are also a number of over-the-counter treatments such as
eye drops and nasal saline spray that can also help to alleviate some of the symptoms. In
emergency cases, epinephrine can be administered to stop the serious allergic reaction of
anaphylaxis (AAAAI, 2018).
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Other treatments aim to stop or limit the allergy symptoms from occurring by
interfering with a step in the molecular pathway of the allergic response. These include
antihistamines, mast cell stabilizers, and antileukotriene agents (AAAAI, 2018).
Antihistamines such as loratadine (Claritin) and cetirizine hydrochloride (Zyrtec) block
histamine from attaching to its receptor after it has been released from the mast cells.
Mast cell stabilizers can stop the histamine from being released from the mast cells in the
first place. Antileukotriene agents work to limit the effects of leukotrienes, which are
known to play an important role in some severe allergic symptoms. Some of these agents
work by blocking the production of leukotrienes while others stop leukotrienes from ever
binding to their receptors (AAAAI, 2018).
Although avoidance and symptom management treatments are able to reduce the
effects of allergic responses, they are insufficient for many and are not measures working
towards a curative or long-lasting therapy. Researchers have been seeking new and
improved therapeutics such as through immunotherapy to better target the foundational
mechanisms initiating allergic reactions which can even work in conjunction with the
aforementioned treatments to increase the efficacy and endurance of treatment.
Allergy Immunotherapy
Allergy-specific immunotherapy (SIT) is a curative method of treatment for
certain allergies as it is able to induce long-term allergen-specific tolerance through
multiple mechanisms and routes of administration (Akdis, 2014). Desensitization with
SIT involves a process similar to vaccinations in which increasing doses of extracts of the
specific allergen are administered followed by maintenance doses for several years. This
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process is hoped to trigger immunological change for sustained desensitization (Orengo
et al., 2018). Immunotherapy, specifically allergy shots or desensitization, is one of the
most effective treatments for those who experience chronic allergies. Currently, there are
even oral tablets such as Grastek and Oralair that can be taken at home (AAAAI, 2018).
SIT focuses on inducing an increase in IgG production to outcompete IgE in
binding to effector cell receptors. Orengo et al. (2018) tested this method in mice and
cat-allergic patients, finding that an increase in the blocking IgG/IgE ratio reduces the
allergic response. Although SIT can provide lasting treatment, it has variable efficacy
among patients. Some patients have no response to treatment, and others have adverse
side effects. Side effects are most commonly associated with food allergies, and therefore
SIT is only available for environmental aeroallergens (Orengo et al., 2018). To address
some of the issues of this technology, more research is emerging on dosing schedules,
routes of administration, and advanced vaccines (Akdis, 2014). While there are
established methods of immunotherapy, improvements can be made for more effective
actions that can be applied to all types of allergens.
Anti-Cytokine Drug Therapy
There is research underway in the vein of genetic exploration among the genes
behind antibody production and class switch recombination. In a 2016 study, the effects
of anti-IL-4 were investigated to combat asthma with variable changes among asthmatic
symptoms across asthma types (Bagnasco et al., 2016). In 2001, clinical trials began
testing anti-IL-4 drug pascolizumab against the effects of allergic asthma with mixed
results that ultimately concluded inefficacy (Hart et al., 2002). Often, therapies with
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action to block IL-4 act in conjunction with inhibitors of IL-13 due to the redundancy that
the two cytokines possess in expressing many of the same pathways, functioning
similarly (Kau & Korenblat, 2015). Several dual-blocking anti-IL-4 and anti-IL-13 drugs
are in the process of testing yet are thus far ineffective in entirely blocking allergic
asthma due to functional differences of various subtypes of asthma which complicate the
efficacy of the drugs (Kau & Korenblat, 2015). Overall there is a lack of consistent
efficacy in asthma studies and even less so within the scope of more complicated
allergies, rendering anti-cytokine therapy unpromising.
Anti-IgE Drug Therapy
Anti-IgE drugs mediate the allergic response by binding to the Cε3 region within
the Fc region of the IgE antibody (Holgate, 2014). One example of this type of drug is
omalizumab, a recombinant humanized monoclonal antibody. It works by binding two of
its molecules to the Fc region of the free-floating IgE so that it is unable to bind to FcεR1.
This reduces the levels of free-floating IgE in the body as over time they are recycled.
This reduction of IgE over time allows the drug to be effective against a long-term allergy
such as allergic rhinitis (Easthope & Jarvis, 2001). Other allergies have been tested
against the effects of omalizumab with varying degrees of success. In a review done in
2014, omalizumab was reported to have anecdotal or limited evidence against allergies
such as Churg-Strauss Syndrome, bronchopulmonary allergic aspergillosis (fungal
sensitivity), and eosinophilic otitis media (Holgate, 2014).
MEDI4212 is an anti-IgE monoclonal antibody that has the potential to eliminate
IgE-expressing B cells and neutralize soluble IgE in asthma prone patients (Nyborg et al.,
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2015). This occurs through cell-mediated cytotoxicity, a type of immune reaction in
which the target is coated with antibodies and killed by white blood cells. MEDI4212
variants also inhibited IgE-induced signaling and demonstrated enhanced cell killing.
(Incorvaia & Mauro, 2015). MEDI4212’s advantage over omalizumab is its ability to
neutralize high amounts of soluble IgE as well as remove the IgE expressing B cells.
(Incorvaia & Mauro, 2015). The authors suggest that this drug is not likely to replace
omalizumab, which has been brought to market, but could potentially be used as an
additional treatment (Nyborg et al., 2015). More research needs to be done on this novel
high-affinity anti-IgE monoclonal antibody, such as testing its abilities to reduce other
allergies other than asthma.
Adenine in Cell Signaling
Adenine has a variety of biological functions other than being a component of
DNA and RNA. A 2015 study shows that adenine possess anti-allergic effects by
inhibiting FcɛRI-mediated signaling events (Silwal et al., 2015). Findings by Silwal et al.
testing the effects of adenine is valuable in the search for finding a medication that
prevents the allergic response from occurring. Rather than antihistamines which merely
alleviate symptoms caused by the degranulation of mast cells, administering adenine
could terminate the allergic response earlier in its pathway.
Potential Targets
After conducting the literature review, including the background on the immune
response as well as current and potential treatments available, the team decided to target
the mast cell degranulation pathway. There are extensive therapeutic options that target
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processes after degranulation occurs; thus, we focused our research on inhibiting the
release of inflammatory molecules. Based on the literature findings for parts of the
pathway, we chose which enzymes to focus our research on based on three factors: the
availability of previously-identified inhibitors for the protein, the protein having a critical
role in the signalling pathway, and a gap in the research on its impact in mast cells. Three
enzymes fit these requirements and warranted further research on their inhibitors: Protein
Kinase C (PKC), Phospholipase C gamma (PLCγ), and Phosphoinositide-3-Kinase
(PI3K). Next, we will examine these known inhibitors and their analogs to optimize their
binding to these target proteins. In this project, we explore how proteins within the
downstream mast cell signaling pathway can be inhibited in order to reduce degranulation
and thus reduce the allergic response. To examine this, the team decided to focus on
computational methodologies.
State of Current Research in Protein Modeling
Virtual screening is a computational method by which binding between ligands
and their macromolecule is simulated. This technique is often used in the context of drug
discovery due to its ability to screen libraries by way of sequential filters to target ligands
with appropriate affinities to a molecule’s binding site (Lavecchia & Di Giovanni, 2013).
There are two main types of virtual screening methods: ligand-based and
structural-based. In ligand-based virtual screening, the properties of known active ligands
are evaluated according to their similarity to new ligands. To operate in a ligand-based
method, an efficient similarity measure and a reliable scoring method are utilized (Hamza
et al., 2012) This method is useful when there is no available structure of the target
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protein molecule. Structure-based virtual screening operates by scoring the affinity of a
known ligand with a known protein target. This predicted ligand-protein complex is
evaluated by calculating the free energy of the docking site when involved by the ligand
in the protein (Lionta et al., 2014). Many computational softwares use both ligand- or
structure-based screening techniques to approximate novel ligand-protein complexes.
PyRx is an open-source virtual screening software that contains Autodock Vina, a
program used for computational docking to simulate receptor-ligand interactions (Trott &
Olsen, 2010). Computational docking software relies on a number of approximations to
predict the confirmation and binding affinity between a target receptor and its ligand.
Autodock Vina assumes a rigid receptor and fixed bond angles and bond lengths in the
ligand to reduce the size of the conformational search space (Cosconati et al., 2010). An
empirical free energy force field with terms for hydrogen bonding potentials,
electrostatics, and torsional entropy predicts the binding affinity between the ligand and
receptor at different conformations. Autodock Vina uses a scoring function based on
predictions from the empirical force field to determine the best binding conformations
and their respective free energies of binding. Since the conformational search methods
are stochastic, the lowest reported binding affinity is not guaranteed to be a global
minimum. The estimated free energies of binding are accurate within 2-3 kcal/mol (Forli
et al., 2016).
Identification of more inhibitors in the pathway through computational modeling
could lead to more effective treatment after in depth study. Thus, the aim of this project is
to identify drug candidate molecules similar in structure to these lead inhibitors from a
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vast library of compounds and to screen them using virtual modeling. Specifically, by
modeling protein-inhibitor interactions using PyRx, we can predict the effectiveness of




The protein sequences (FASTA sequences) of the macromolecules tested—PI3K,
PKC-beta1 (β1), PKC-beta2 (β2), PKC-delta (δ), PKC-eta (η), PLC-gamma1 (γ1),
PLCgamma2 (γ2)—were derived from the National Center for Biotechnology
Information (NCBI) database or Research Collaboratory for Structural Bioinformatics
(RCSB) database. These protein sequences were then modeled using Phyre2, a 3D
protein modeling software (Kelley et al., 2015). Putting the resulting protein models
through Modrefiner, an algorithm for atomic-level, high-resolution protein structure
refinement, provided a more reliable model of the signaling molecule, as we determined
using the following protein structure analysis programs: ProSA, ProCheck, and ERRAT
server (Xu & Zhang, 2011). ProSA determined local quality of sections of the protein so
that it can be seen if any areas specifically are incorrectly modelled (Wiederstein & Sippl,
2007). ProCheck created Ramachandran plots to check accuracy of bond angles
(Laskowski et al., 1996). ERRAT server measured the accuracy of nonbonded
intermolecular forces (Colovos & Yeates, 1993). All of these analysis programs together
provided a comprehensive picture of the accuracy of the protein models made by Phyre2
and ModRefiner.
Preparing Ligands for Docking
These refined models were then screened in PyRx, a virtual molecular screening
software which predicts binding affinity, against known inhibitors whose structures were
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derived from PubChem (Dallakyan & Olson, 2014). The chosen proteins were imported
into PyRx as .pdb files and converted into AutoDock macromolecules.
The established inhibitors for the selected pathway were designated as the
‘ligands’ within PyRx and were screened against the signaling molecules, termed
‘macromolecules’ in the software. ‘Ligands’ were imported into PyRx from PubChem in
the form of SDF files. Intramolecular forces within the ligands were then minimized
through OpenBabel by setting the total number of steps to 10,000 and the stop criterion at
an energy difference of less than 0.01. These parameters were modified in the PyRx
software in order to optimize the orientation of the ligand for binding interactions. The
ligand was then converted into an AutoDock ligand to begin virtual screening. For the
screening process, we used the Vina Wizard program within PyRx. We selected the
macromolecule and ligand whose binding was to be modeled and maximized the region
of protein to be analyzed for potential binding sites, although not necessarily the ATP
binding pocket of the kinases modeled, as well as increased exhaustiveness of binding
site identification to 12 before starting the run. A list of binding affinities was generated,
and we recorded the most favorable ΔG value, indicative of the highest predicted affinity
between the ligand and the macromolecule.
Analogs
Several ligands were selected to be run with each protein specified. Eleven
simulation trials were run in PyRx modeling affinity software for each ligand-protein
pair. Out of 34 known inhibitors, the average binding affinity was calculated across
eleven trials. Out of 15 selected inhibitors, analogs were derived from the ZINC database.
27
Analogs tested had similarity thresholds above 0.3, by ZINC standards. These analogs
were then tested for binding energy to the signaling molecules in PyRx using a similar
methodology as described above; however, exhaustiveness was set to 16 and an average
of predicted ΔG values was taken across 5 trials.
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Results
We were interested in identifying novel inhibitors that might point to new
therapeutic avenues for treating allergies. In order to investigate this, we took a
computational approach.
Protein Structure Analysis
We began by using Phyre2 and Modrefiner to develop and refine 3D models of
the signaling molecules involved in the degranulation pathway, as many of the selected
molecules did not have reliable existing file type PDBs of the selected molecules; in
order to maintain consistency in our modeling, we chose to create 3D models for all
selected signaling molecules. The Phyre2 server, a protein structure prediction web
portal, was used to predict the 3D structure of a single submitted protein sequence
(Kelley et al., 2015). The 3D structures were subsequently put through Modrefiner, which
aimed to enhance the models by altering them to be closer to their native states by
altering hydrogen bonds, backbone topology, and side chain positioning (Xu & Zhang,
2011). Models were then evaluated through ProCheck, ProSA, and ERRAT─which
determine the validity of the 3D protein models through evaluation of local quality of
sections of the protein, accuracy of bond angles, and accuracy of nonbonding
intermolecular forces, respectively─and indicated that ModRefiner greatly increased the
quality of the protein model PDB files in relation to the models that were only made with
the Phyre2 software. This made the signaling protein models more valid for binding
studies. The results of the protein structure analysis programs are shown in Appendix C.
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Notably, many of the Ramachandran plots generated from the 3D models of the
signaling molecules, even after refinement, indicated regions of error above acceptable
levels. However, despite this limitation in our models, we proceeded forward with
modeling as proof of concept of the modeling procedure due to time limits and lack of
computational power for modeling.
Binding Energy of Established Inhibitors
We then identified known inhibitors for signaling proteins in the selected pathway
and predicted the binding energy using PyRx, a virtual molecular screening software (See
Appendix B for complete list). This screening allowed us to establish a baseline for
finding novel inhibitors. Shown in Table 1 are the average ΔG values of the established
inhibitors with the highest affinities to the signaling molecules across eleven trials. For
each signaling macromolecule, the best one or two inhibitors were selected for further
study in order to determine what, if any, changes to the structure would lead to a stronger









PI3K Wortmannin -7.62 0.36± 1.35E-06
PI3K ZSTK474 -8.41 0.18± 4.89E-07
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PKC-β1 Enzastaurin -10.15 0.38± 3.54E-08
PKC-β1 Ruboxistaurin -9.50 0.06± 8.54E-08
PKC-β1 Midostaurin -9.63 0.06± 8.54E-08
PKC-β2 Enzastaurin − 9. 40 ± 0. 31 1.27E-07
PKC-β2 Sotrastaurin -8.90 0.46± 6.44E-08
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PKCδ Sotrastaurin -10.00 0.67± 1.41E-08
PKCδ Rottlerin -9.36 0.54± 1.27E-07
PKCη Sotrastaurin -9.03 0.25± 2.38E-07
PLC-γ1 U73122 -8.60 0.45± 1.78E-07
PLC-γ2 U73122 -8.20 0.31± 4.89E-07
Table 1. The binding energy of known inhibitors to macromolecules in the mast cell
signalling pathway
Analogs of Selected Inhibitors
In order to identify novel inhibitors that could serve as potential therapeutics
against the signaling molecules of the degranulation pathway, we utilized the ZINC
Database to search for analogs of the established inhibitors we selected. We searched for
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analogs that had a similarity-30 by ZINC database standards, which means ZINC
database defined them to be at least 30% similar to the ligand. When we did this, we
increased the exhaustiveness for binding from 12 to 16 in the PyRx software to ensure
that we were truly identifying the best binders.
PI3K Inhibitor: Wortmannin
We examined 30 analogs of Wortmannin from the ZINC Database. Of these 30
analogs, there were four analogs that had better binding affinities than Wortmannin.
Inhibitor Structure Binding Energy (kcal/mol)
Wortmannin -7.62 0.36±
Analog
ZINC8035078 − 8. 08 ± 0. 38
ZINC257519889 − 8. 18 ± 0. 16
ZINC144119389 − 8. 26 ± 0. 05
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ZINC71789745 − 7. 90 ± 0. 42
Table 2. Average binding affinities after molecular docking of  Wortmannin and analogs
to PI3K. An average of five trials was taken for the binding affinities of each analog with
corresponding standard deviation values.
Figure 4. Image to the left shows binding of ZINC144119389 which had the lowest
binding energy and image to the right shows binding of ZINC257519889 to PI3K.
The binding energy of Wortmannin to PI3K was measured to be -7.62 kcal/mol
over five trials. The analog that decreased binding energy the most was ZINC144119389
with an increase of about 0.94 kcal/mol from that of Wortmannin. Another analog with a
strong binding energy was ZINC257519889 with an increase of 0.86. The figure above
shows the binding site for the two analogs with the lowest binding energy. When
comparing the values we found in the literature, wortmannin had a binding energy of
−10.9 and −11.7 kcal/mol.
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PI3K Inhibitor: ZSTK474
We examined 17 analogs of ZSTK474 from the ZINC Database. Of these 17
analogs, there were 5 analogs with higher binding affinities upon docking with PI3K than
that of ZSTK474.









Table 3. Average binding affinities after molecular docking of  ZSTK474 and analogs to
PI3K. An average of five trials was taken for the binding affinities of each analog with
corresponding standard deviation values.
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Figure 5: Image to the left shows the binding of ZINC1243947389, which had the lowest
binding energy, on to PI3K. Image to the right shows the binding of all the six
compounds, ZSTK474 and its examined analogs, on to PI3K.
The binding energy of ZSTK474 to PI3K was measured to be -8.41 kcal/mol over
five trials. Figure 5 shows that all examined analogs of ZSTK474, as well as ZSTK474
itself, bind to the same area on the PI3K molecule. The ZSTK474 analogs with better
binding affinities differed in structure through changes to the triazine ring or its
substituents, which may have led to their higher binding affinities. The analog that
decreased binding energy the most was ZINC1243947389 with an increase of about 0.41
kcal/mol from that of ZSTK474.
PKCβ1 Inhibitor: Enzastaurin
We examined six analogs of Enzastuarin from the Zinc Database. Of these six
analogs, there were three analogs that had a binding energy that was at least as strong as
Enzaustaurin itself.
Inhibitor Structure Binding Energy (kcal/mol)
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Enzastuarin − 10. 16 ± 0. 40
Analog
ZINC13489985 − 10. 36 ± 0. 05
ZINC13489986 − 10. 16 ± 0. 31
ZINC13489987 − 10. 42 ± 0. 54
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Table 4. Average binding energies after molecular docking of enzastaurin and analogs to
PKCβ1. An average of five trials was taken for the binding energies of each analog with
corresponding standard deviation values.
Figure 6. The image on the left shows Enzastaurin (shown in the molecular surface
model) interacting with PKCβ1 (in the ball and stick model). The image on the right
shows the analog ZINC13489987  interacting with PKCβ1.
Binding of PKCβ1 to ZINC13489987 had the lowest energy of -10.42 kcal/mol,
which is a 0.26 kcal/mol increase compared to the binding energy of enzastaurin. This
analog has a carbon instead of a nitrogen in the benzene ring. It also has a wedge
stereochemistry change at one position, where the six carbon ring is replaced with a five
carbon ring. As depicted in Figure 6, the analog does bind in the active site, and it likely
interacts with a different orientation, therefore possibly different residues within that site
that allow it to have a lower binding energy..
PKCβ1 Inhibitor: Ruboxistaurin
We examined 15 analogs of Ruboxistaurin from the Zinc Database, with five trials
each. Of these fifteen analogs, there were five analogs that had a negative binding energy
that was significantly stronger than Ruboxistaurin itself.










Table 5. Average binding affinities after molecular docking of Ruboxistaurin and analogs
to PKCβ1. An average of five trials was taken for the binding affinities of each analog
with corresponding standard deviation values.
Figure 7. This image above shows the binding of ZINC3825435, which had the lowest
binding energy, on to PKCβ1.
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Binding of PKCβ1 to ZINC3825435 had the lowest energy of -10.1 kcal/mol,
which is a 0.6 kcal/mol increase compared to the binding energy of ruboxistaurin. This
analog has a hydroxyl group instead of a tertiary amine attached to the cyclic ring next to
the oxygen. The stereochemistry of the hydroxyl group is conserved as it remains on the
dashes.
PKCβ1 Inhibitor: Midostaurin
We examined 15 analogs of midostaurin binding to PKCβ1. Below are the 5
analogs that caused the greatest decrease in binding energy compared to base
midostaurin.
Inhibitor Structure Binding Energy (kcal/mol)
Midostaurin -9.44 0.34±
Analog






Table 6. Average binding affinities after molecular docking of  Midostaurin and analogs
to PKCβ1. An average of five trials was taken for the binding affinities of each analog
with corresponding standard deviation values.
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Figure 8. Image at the top shows the binding of ZINC27326075, which had the lowest
binding energy, on to PI3K. Image at the bottom shows the binding of all the compounds,
Midostaurin and its examined analogs, on to PKCβ1.
Binding of midostaurin to PKCβ1 was measured with a ΔG of -9.44 kcal/mol over
5 trials. Each analog of midostaurin, as well as midostaurin itself, bind to the same area
on the PKCβ1 molecule. The analog that decreased binding energy the most was
ZINC27326075, which differs from base midostaurin in that it has an extra chloride
group coming off one of its aromatic rings, as seen in Figure 8. This leads to a binding
energy increase of about -1.48 kcal/mol, from -9.44 kcal/mol for midostaurin to -10.92
kcal/mol for the analog.
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PKCβ2 Inhibitor: Enzastaurin
We examined the same six analogs of Enzastuarin from the Zinc Database,
however this time they were tested with PKCβ2.  Two analogs, ZINC13489985 and
ZINC13489987, were found to bind better to PKCβ2 than enzastaurin itself.
Inhibitor Structure Binding Energy (kcal/mol)
Enzastaurin − 9. 40 ± 0. 31
Analog
ZINC13489985 − 10. 34 ± 0. 25
ZINC13489987 − 10. 16 ± 1. 14
Table 7. Average binding affinities after molecular docking of  Enzastaurin and analogs
to PKCβ2. An average of five trials was taken for the binding affinities of each analog
with corresponding standard deviation values.
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Figure 9. Image to the left shows the binding of ZINC13489985, which had the lowest
binding energy, on to PKCβ2. Image to the right shows the binding of both analogs of
enzastaurin, ZINC13489985 and ZINC13489987, on to PKCβ2.
The binding energy of enzastaurin to PKCβ2 was measured to be -9.40 kcal/ mol
over five trials. Each analog of enzastaurin binds the site on the PKCβ2 molecule. The
analog that had the best binding energy was ZINC13489985, with an increase of about
-0.94 kcal/ mol from enzastaurin. The change made to enzastaurin to create this analog is
replacing a nitrogen with a carbon in the benzene ring.
PKCβ2 Inhibitor: Sotrastaurin
We examined 9 analogs of Sotrastaurin from the ZINC Database, with five trials
for each. Of these analogs, there were two molecules with significantly greater binding
affinities upon docking with PKCβ2 than that of sotrastaurin.
Inhibitor Structure Binding Energy (kcal/mol)
Sotrastaurin − 8. 74 ±  1. 80
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Analog
ZINC36477833 − 11. 16 ± 0. 32
ZINC955736 − 9. 28 ± 0. 39
Table 8. Average binding affinities after molecular docking of  Sotrastaurin and analogs
to PKCβ2. An average of five trials was taken for the binding affinities of each analog
with corresponding standard deviation values.
Figure 10. This image shows the analog ZINC36477833 (in the ball and stick model)
interacting with PKCβ2 (shown in the molecular surface model).
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Binding of sotrastaurin analogs to PKCβ2 were measured across five trials.
ZINC36477833 has the lowest binding energy to PKCβ2 with a value of -11.16. This
analog differs from sotrastaurin in its lack of a methyl group on a cyclic nitrogen,
resulting in a 2.42 kcal/mol binding increase. The analog with the second lowest binding
energy is ZINC955736, which differs from Sotrastaurin within many aspects of its
structure, resulting in an increase of 0.54 kcal/mol. The major changes in the molecule
include the addition of three fluorines, the removal of two cyclic structures, and the
addition of an ester.
PKCδ Inhibitor: Sotrastaurin
We examined the binding energy of sotrastaurin and 10 of its analogues to PKCδ.
Among these analogues, ZINC95573621 and ZINC36477833 had higher binding
affinities to PKCδ compared to sotrastaurin. Another sotrastaurin analogue,
ZINC95571944, exhibited a slightly lower but comparable binding affinity to PKCδ. We
confirmed that sotrastaurin and all three reported sotrastaurin analogues have the same
binding site on PKCδ.







Table 9. Average binding affinities after molecular docking of  Sotrastaurin and analogs
to PKCδ. An average of five trials was taken for the binding affinities of each analog with
corresponding standard deviation values.
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Figure 11. Image to the left shows the sotrastaurin analog ZINC95573621 interacting
with PKCδ. Image to the right shows sotrastaurin and its three examined analogs bind to
the same site on PKCδ.
The binding energy of sotrastaurin to PKCδ was measured to be -9.78 kcal/mol
over five trials. The lowest binding energy was observed to be ZINC95573621 with a
measured binding energy of -10.18 kcal/mol. The structure of ZINC95573621 differs
from the structure of sotrastaurin by the addition of a chlorine substituent.
PKCδ Inhibitor: Rottlerin
We examined 13 analogs of Rottlerin from the ZINC Database. Of these 13
analogs, there were 5 analogs with higher binding affinities upon docking with PKCδ
than that of Rottlerin.









Table 10. Average binding affinities after molecular docking of Rottlerin and analogs to
PKCδ. An average of five trials was taken for the binding affinities of each analog with
corresponding standard deviation values.
Figure 12. This image shows the analog ZINC33832041 (in the ball and stick model)
interacting with PKCδ (shown in the molecular surface model).
The binding energy of Rottlerin to PKCδ was measured to be -9.3 kcal/mol over
five trials. The analog that decreased binding energy the most was ZINC33832041 with an
decrease of about 1.4 kcal/mol from that of Rottlerin. All analogs bound to PKCδ at the
same binding site. The largest change in structure from Rottlerin to its analogs was the
construction of a cyclohexane via a nucleophilic attack of an alkene by a hydroxyl group,
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which was found in three of the analogs that increased binding affinities compared to
Rottlerin.
PKCη Inhibitor: Sotrastaurin
We examined 26 analogs of sotrastaurin binding to PKCη. Below are the 5
analogs that caused the greatest decrease in binding energy compared to base sotrastaurin.










Table 11. Average binding affinities after molecular docking of Sotrastaurin and analogs
to PKCη. An average of five trials was taken for the binding affinities of each analog with
corresponding standard deviation values.
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Figure 13. Image to the top shows the binding of ZINC13489990, which had the lowest
binding energy, on to PKCη. Image to the bottom shows the binding of all the
compounds, Sotrastaurin and its examined analogs, on to PKCη.
Binding of sotrastaurin to PKCη was measured with a ΔG of -9.24 kcal/mol over
5 trials. The figures show that each analog of midostaurin, as well as midostaurin itself,
bind to the same area on the PKCη molecule. The analog that decreased binding energy
the most was ZINC13489990, which differs from base sotrastaurin in that it has a
cyclohexane converted to a cyclopentane, as well as the loss of two nitrogen groups, as
seen in Figure 13. This leads to a binding energy decrease of about -1.36 kcal/mol, from
-9.24 kcal/mol for midostaurin to -10.58 kcal/mol for the analog.
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PLC𝛾1 Inhibitor: U73122
We examined 26 analogs of U73122 from the ZINC Database. Of these 26
analogs, there were three analogs with lower binding energies upon docking with PLC𝛾1
than that of U73122.
Inhibitor Structure Binding Energy
(kcal/mol)
U73122 − 8. 63 ± 0. 47
Analog
ZINC575440631 − 9. 10 ± 0. 43
ZINC145390416 − 8. 66 ± 0. 87
ZINC31356813 − 8. 64 ± 0. 62
Table 12. Average binding energies after molecular docking of U73122 and analogs to
PLC𝛾1. An average of five trials was taken for the binding energies of the analogues.
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Figure 14. This image shows the analogs ZINC575440631, ZINC145390416, and
ZINC31356813 (in the ball and stick model) interacting with PLC𝛾1 (shown in the blue
molecular surface model).
Binding of U73122 to PLC𝛾1 was measured with a ΔG of − 8. 63 ± 0. 47
kcal/mol over eleven trials. Binding of U73122 analogs to PLC𝛾1 were measured across
five trials. As shown in figure 14, analogs ZINC145390416 and ZINC31356813 bind to
the same binding pocket of the PLC𝛾1 molecule. The ZINC575440631 analog was
predicted to be bound at a different location of the signaling molecule as its primary
binding mode. The analog that was measured to have the lowest binding energy to PLC𝛾1
was ZINC575440631 which differs from base U73122 structure with respect to the
presence of an alkene, as seen in table 12. This resulted in a binding energy change of
about -0.47 kcal/mol, from kcal/mol for U73122 to− 8. 63 ± 0. 47 − 9. 10 ± 0. 43
kcal/mol for the analog. The analog with the second lowest binding energy with PLC𝛾1,
among 26 analogs tested, was ZINC145390416 which differs from base U73122 in
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stereochemistry, as seen in Table 12. This resulted in a binding energy change of about
-0.03 kcal/mol, from kcal/mol for U73122 to− 8. 63 ± 0. 47 − 8. 66 ± 0. 87
kcal/mol for the analog. The analog with the third lowest binding energy with PLC𝛾1,
among 26 analogs tested, was ZINC145390416 which also differs from base U73122 in
stereochemistry, as seen in table X. This resulted in a binding energy change of about
-0.01 kcal/mol, from kcal/mol for U73122 to− 8. 63 ± 0. 47 − 8. 64 ± 0. 62
kcal/mol for the analog.
PLC𝛾2 Inhibitor: U73122
We examined 26 analogs of U73122 from the ZINC Database. Of these 26 analogs, there
was one analog with a decreased binding energy upon docking with PLC𝛾2 than that of
U73122.
Inhibitor Structure Binding Energy (kcal/mol)
U73122 − 8. 18 ± 0. 32
Analog
ZINC575440631 − 8. 46 ± 0. 31
Table 13. Average binding energies after molecular docking of U73122 and analogs to
PLC𝛾1. An average of five trials was taken for the binding energies of the analogues.
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Figure 15. This image shows the analog ZINC575440631 (in the ball and stick model)
interacting with PLC𝛾2 (shown in the blue molecular surface model).
Binding of U73122 to PLC𝛾2 was measured with a ΔG of − 8. 18 ± 0. 316
kcal/mol over eleven trials. Binding of  U73122 analogs to PLC𝛾2 were measured across
five trials. The ZINC575440631 analog binds to the same binding pocket of the PLC𝛾2
signaling molecule as established inhibitor U73122. ZINC575440631, which differs from
the base U73122 structure with respect to the presence of an alkene, was the only analog
of the 26 screened that was predicted to have decreased binding energy to PLC𝛾2 than
U73122. The screening software predicted a binding energy change of about -0.28




Once the binding energy of a ligand and each of its analogs to the target protein
was calculated, analogs were ranked by how they changed binding affinity. Some analogs
introduced structural changes that greatly enhanced binding to the target protein, as
evidenced by a much more negative ΔG of interaction compared to the original ligand
structures. The analogs that increased binding affinity were selected, and their binding fit
was observed in PyRx. This was done by loading the file with the modelling results for
one analog into PyRx with the target protein structure. This allowed direct visualization
of the predicted best binding sites on the target protein that PyRx found for each ligand
and analog. From here, it can be observed the molecular character of the binding site,
such as the regions of hydrophobicity, polarity, and aromaticity, based on which amino
acid residues comprise the binding site. It can be observed which parts of the ligand bind
to each amino acid in the binding site, as well as how a ligand analog binds differently in
the binding site. This allowed characterization of how each structural change afforded by
each analog improved certain electrostatic interactions that contributed to the overall
increase in binding affinity.
Our findings suggest that there are many novel and existing molecules that can be
used to reduce the release of histamines and cytokines responsible for the allergic
response, and further modification of these molecules may increase their inhibition
capacities. In general, each inhibitor used as a ligand for each protein macromolecule had
at least two analogs that increased binding to that protein. In some cases the binding
affinity of the ligand’s analog increased by over 1 kcal/mol compared to the ligand,
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corresponding to at least a tenfold increase in ligand affinity for the protein. This
indicates that there is much room for improvement of existing inhibitors for these
proteins, and modifications can easily be made to them to reach analog structures. Such a
large increase in affinity observed by the analog bindings indicates that these potential
inhibitors can be made much more effective and reach the status of potent drug inhibition.
Analog acquisition can be done several ways: by chemical synthesis or through
purification from biological organisms.
Between inhibitors and their analog structures, there was also a pattern of some
intermolecular forces always being retained. The binding sites of these proteins were very
specific in character, often containing regions of high aromaticity, and of negative,
positive, and neutral charge. Likewise, these potential inhibitors bound so well to their
respective proteins because they also contained complementary regions to the protein
binding sites. Even if analogs changed some structure of the inhibitors, these main
intermolecular interactions between protein and inhibitor were maintained, and
contributed to the bulk of the free energy of binding. Specific breakdowns of each
inhibitor and its analogs can be found below.
PI3K - Wortmannin
By examining the structures we found that the Wortmannin analogs with the most
negative binding energy, ZINC257519889 and ZINC144119389, differed from
Wortmannin’s structure by a change in the stereochemistry. A change of the ether
substituent from a wedge to a dash made the analog bind more strongly. In
ZINC144119389, having both the ether and ketone substituents moved from a wedge to a
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dash led to decreased binding energy. The results suggest that changes in stereochemistry
were effective at increasing the binding of Wortmannin to PI3K. The binding site of
ZINC8035078,  ZINC144119389, and ZINC71789745 were the same and were a
different binding site than ZINC257519889 and ZINC3875294. Both of these analogs
were bound at two different sites on PI3K. Studies have shown that there are at least five
different binding pockets in PI3K which can all allow for inhibition, including allosteric
inhibition (Miller et al., 2017).
PI3K - ZSTK474
The PI3K binding area that ZSTK474 and its examined analogs bound to was
conserved, as they all bound to the same pocket. By examining their structures, it was
found that the ZSTK474 analogs with the most negative binding energy,
ZINC1772653009, ZINC73160255, and ZINC1243947389, differed in structure through
changes to the triazine ring or its substituents which may have led to their higher binding
affinities. In ZINC73160255, there is a pyrimidine instead of the triazine ring which may
have made the analog bind more strongly as it became bound deeper within the PI3K
binding area. In ZINC1772653009, the morpholine substituent on the triazine ring has
been changed to an aminopiperidine, which may have made the analog bind more
strongly. In ZINC1243947389, the morpholine substituent on the triazine ring has been
changed to a tetrahydropyridine, which may have led to increased binding energy, the
highest amongst the set of ZSTK474 analogs tested. The substituent changes on the
analogs are interestingly on the part of the ZSTK474 inhibitor that protrudes out of the
binding area pocket of PI3K.
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PKCβ1 - Enzastaurin
By examining the structures we found that the analogs with the most negative
binding energies differed from Enzastaurin’s structure by a substitution of the nitrogen in
the benzene ring for a carbon, which made the molecule less charged/polar, and by a
change in the stereochemistry. A change of the ether substituent from a wedge to a dash
made the analog bind more strongly. Because Enzastaurin is already a good inhibitor of
PKCβ (IC50 of 50 nM), the analogs didn’t need to have major modifications in order to
demonstrate stronger binding affinities.
PKCβ1 - Ruboxistaurin
There were several structural changes that resulted in decreased binding energy.
These changes mainly involve stereochemistry and substituent substitutions. The analog
with the strongest binding energy, ZINC3825435, substituted the tertiary amine with a
hydroxyl group. This group protrudes out of the binding area pocket of PKCβ1. Similarly,
the analog with the second highest binding energy, ZINC13604307, substituted the same
tertiary amine with an amino group. The analog was attached to the same binding pocket
on the PKCβ1 protein as ZINC3825435. However, the amino group did not protrude
outwards like the hydroxyl group. The other analogs had changes in either
stereochemistry, other substitutions, or a combination of both. These findings suggest that
the change to Ruboxistaurin with the most significance when binding PKCβ1 is the
substitution of the tertiary amine with a hydroxyl or amine group.
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PKCβ1 - Midostaurin
The PKCβ1 binding area that midostaurin and all of its analogs bound to was
conserved, as evidenced by the figures, and had several particular characteristics. There
was a region with many aromatic amino acids pointing into the pocket, and another
region that had many negatively charged amino acids and oxygens. For all of the analogs,
there was always some interaction between the aromatic area of the ligand and the
aromatic amino acids of the PKCβ1 binding pocket, indicating that this interaction was
very important to the binding energy of midostaurin and its analogs to PKCβ1. For
midostaurin, the ligand oriented itself so that its aromatic region was as close to all of the
aromatic amino acids in the pocket as possible. There was very little interaction with the
negatively charged amino acids of the binding pocket. In the analog ZINC253614774, the
change in stereochemistry led to the observance of an extra aromatic interaction between
the lone end benzene on the left of the molecule and the binding pocket, which likely
resulted in the observed decrease in binding energy is probably a big reason for binding
energy decrease between ligand and protein. The change in stereochemistry caused the
analog ZINC100080802 to orient differently in the binding pocket than midostaurin.
Despite the additional chloride group, the analog ZINC27326075 took the same
conformation in the binding pocket as ZINC253614774, so it is unclear why it has the
highest affinity for PKCβ1 out of all the tested midostaurin analogs. In the analog
ZINC1569989194, methylation caused the ligand to take a different conformation in the
binding pocket than other analogs, with the aromatic region pointing outwards, and this
was also the case for ZINC584567048, which had an extra carbonyl group on the pentane
64
near the aromatic region of the ligand. It is noticeable that most of the analogs, and
midostaurin itself, prefer to orient with their aromatic regions overlapping that of the
protein. For most of the analogs as well, there was not very clear engagement of the
negatively charged region of the PKCβ1 binding pocket, and it did not interact visibly
with the ligands.
PKCβ2 - Enzastaurin
Through examination of the structures, the analogs with the most negative binding
energies differed from Enzastaurin’s structure either in a substitution of an atom or by
ring size. The ZINC13489985 analog has a carbon in the benzene ring instead of the
nitrogen that was present in Enzastaurin, which made the ligand less polar. The
ZINC13489987 analog has replaced a cyclohexane with a cyclopentane leading to a
newly formed stereocenter, which may have contributed to the increased binding affinity
to PKCβ2.
PKCβ2 - Sotrastaurin
Of the two high affinity potential inhibitors, the analog with the highest affinity,
ZINC36477833, differed from Sotrastaurin structure through the lack of a methyl group
on a cyclic nitrogen. Changes in the structure from a methyl to a hydrogen is a
contribution of the stronger binding affinity, likely due to increased hydrogen bond
capacity. While the second analog, ZINC955736, did have an increased binding affinity
as well, major changes in its structure were only responsible for a 0.54 kcal/mol
improvement in binding affinity. These changes included the addition of three fluorines,
the removal of two cyclic structures, and the addition of an ester, which made the
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molecule more polar overall. Therefore, the small change of the methyl-group removal
appears to have a much greater impact than the many major adjustments found on
ZINC955736.
PKCδ - Sotrastaurin
The central maleimide group on Sotrastaurin forms a hydrogen bond with
ASN478 in the PKCδ binding pocket. This interaction is important for ligand binding to
PKCδ because the maleimide group is conserved across all the analogues that had higher
binding affinities compared to Sotrastaurin. Two analogues differed from Sotrastaurin by
the addition of a chlorine substituent on the indoline group. The added chlorine
substituent on these analogues may improve binding by steric or electronic effects. The
chlorine atom fills up a large volume, and may provide a tighter fit to the residues in the
binding pocket. The large size of the chlorine atom may also contribute to van der Waal
interactions between the chlorine and nonpolar residues during binding.
PKCδ - Rottlerin
By examining the structures we found that the analogs with the lowest binding
energy, ZINC33832041 and ZINC238744931, differed from Rottlerin’s structure by the
attack of the existing alkene by the hydroxyl within Rottlerin’s structure to form a novel
ring. From there, ZINC33832041 and ZINC238744931 alter stereochemistry by adjusting
to a dash or wedge onto the phenyl group, which may decrease binding energy.
Furthermore, Rottlerin contains a hydroxyl group on one benzene whereas in
ZINC238744931 it has been exchanged for a methyl group. It is unclear if this leads to
lower binding energy since the analog with the lowest binding energy, ZINC33832041,
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contains the hydroxyl. Finally, ZINC238753381 does not contain the newly formed
cyclohexane, yet the decreased binding energy may come from the change in
constituents, two hydroxyls added which increase hydrogen bonding capacity.
PKCη - Sotrastaurin
The main binding site for sotrastaurin and its analogs on PKCη is conserved, as
observed by the figures. Inspection of this binding site on PKCη in PyRx reveals that it
contains a region of aromatic amino acids, as well as a region of nonpolar and region of
negatively charged amino acids. Within all of the analogs of sotrastaurin, it appears that
the amine group on the pentane ring at the top of the molecule always forms a hydrogen
bond with a section of the binding pocket of PKCη, so this is probably a large factor in
the free energy of ligand-protein interaction. The aromatic section of the binding pocket
does not appear to interact strongly with sotrastaurin at all, as the ligand and all its
analogs are separated by a large physical space from the aromatic amino acids of PKCη.
In the analog ZINC95571944, the addition of a chlorine group caused the substrate to
orient differently in the binding pocket than normal sotrastaurin, which might have been
part of the increased affinity of the ligand-protein in. In ZINC45318117, the replacement
of a nitrogen with an oxygen leads to an electrostatic interaction with a PKCη amine
group in the binding pocket. The analogs ZINC95574708 and ZINC95578909 both added
methyl groups in different places of the ligand, which changed the orientation of the
analog of sotrastaurin binding to the pocket. As stated before, the analog with the highest
increase in binding affinity, ZINC13489990, differs from base sotrastaurin in that it has a
cyclohexane converted to a cyclopentane, as well as the loss of two nitrogen groups,
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leading to a different conformation in the PKCη binding pocket. The aromatic residues of
the binding pocket did not play a major, observable role in binding for any of these
analogs. The addition of  minor substituent groups to the sotrastaurin ligand to make
nearly identical analogs still caused large changes in the conformation of the ligand in the
protein binding pocket, indicating that binding is flexible many different modes of
binding can occur.
PLC𝛾1 - U73122
Upon examination of the structures of these low binding energy analogues, we
observed that the analog with the highest affinity to PLC𝛾1 amongst the set of U73122
analogs tested was ZINC575440631. It differed from U73122’s structure through a
change to one of its substituents. In this analogue, the ether substituent bound to an
aromatic carbon has been changed to an alkene. Analogs ZINC145390416 and
ZINC31356813 differed from the structure of U73122 simply by a change in
stereochemistry. Changes in the structure from wedges to dashes resulted in the analogs
binding more strongly.
PLC𝛾2 - U73122
Upon examination of the structure of ZINC575440631, the lowest binding energy
analog amongst the set of U73122 analogs tested, we observed that it differs from
U73122’s structure through a change to one of its substituents. In this analog, the ether
substituent bound to an aromatic carbon has been changed to an alkene. Notably, this
analog was also predicted to have the lowest binding energy, among the 26 analogs
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tested, with PLC𝛾1. This is indicative of the degree of low binding energy of this analog
with PLC𝛾 isoforms.
These findings might aid in the development of a new allergy medication, perhaps
with more efficacy than ones currently on the market. For each of the inhibitors tested,
there was at least one analog that bound more tightly to the target protein than the
inhibitor itself. These analogs can be easily synthesized for future testing. Furthermore,
treatments targeting the molecules we examined have the potential to be administered
prophylactically, and still be useful even after exposure to allergens
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Future Directions
The first thing that can be done with these results is to test a combination of
analog modifications. The research conducted in this project identified analogs to existing
inhibitors for proteins of the mast cell degranulation pathway. These analogs are discrete
and most of them do not overlap, so the modifications made from the base inhibitor to
create them can be combined. In this way, beneficial changes can be combined to make a
potential inhibitor that would be even more potent than any of the analogs individually.
The structures of the analogs that increased binding affinity the most could be
combined in an effort to further boost ligand-protein binding by putting together
individually beneficial structural changes. This can be done by importing the structure of
each ligand into a molecular editing software like PYMOL. Once within PYMOL, the
structure of the ligand could be changed and then saved as a separate file. In this way, the
molecular changes of multiple analogs could be combined to create new potential
structures to test. The affinity of these new structures would then be modelled in PyRx to
see if the summation of the molecular changes was truly beneficial. The analog
combination can be repeated with several different structural variants in an attempt to
find an optimized ligand structure. In addition, user-suggested changes could be
implemented based on observations of the character of the primary binding site on the
protein that the ligand attached to. If a binding site was rich in aromatic amino acid
residues, then a custom modification of the ligand could be made in PYMOL outside of
those provided by the analogs of ZINC database, such as an addition of a benzene or
naphthalene ring to the ligand structure. However, any and all of these structural
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modifications shared the same underlying principle of enhancing the observed
intermolecular interaction between the ligand and protein at the main binding site, so any
favorable analog combinations or custom structures would be made with the intent of
optimizing at least one of these interactions in an attempt to improve the overall ΔG of
binding.
These “custom” potential inhibitors can also be modified based on the observed
characteristics of the binding site on the protein. For example, the binding pocket of
PKCβ1 had many negatively charged amino acids that midostaurin did not interact with,
and the binding pocket of PKCη had a region of aromaticity that sotrastaurin did not
interact with as well. The information gained from this project with regard to combining
analogs and tailoring inhibitors to their binding sites would be very useful in future
creation of better inhibitors for these proteins. An example of this is the structure the
custom sotrastaurin analog shown below:
Figure 16: Structure of two custom analogs modelled off sotrastaurin and optimized to
maximize interactions with the PKC eta binding pocket.
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Both of these sotrastaurin analogs were designed based on the research done in
this study. They combine multiple beneficial traits of sotrastaurin analogs from the ZINC
database, such as methylation and removal of nitrogen in selective locations. They also
are designed with the binding pocket structure of PKCη considered. The addition of an
aromatic group rather than a cyclohexane is intended to help drug binding to aromatic
residues in the binding pocket and enhance overall total affinity. Similar structural
modifications can be made to other potential inhibitors targeting other proteins based on
the research result of this study, which will enhance drug design by allowing scientists to
better understand and optimize the intermolecular forces between proteins and their
inhibitors.
The results compiled from this project are purely theoretical, so the next step after
theoretical drug design would be to actually synthesize the ligands with the highest
affinity for proteins. The protein modelling in PyRx yielded analogs to several known
inhibitors that are predicted to have a higher free energy release upon binding their target
proteins. These potential inhibitor analogs have not yet been made though, so it would be
recommended to use the existing inhibitors as a base to make their analogs. Once the
analogs are made, they can then be tested in actual analytical devices to see if their free
energy of binding to the target proteins match the PyRx predictions. This could be done
using analytical devices like NMR (nuclear magnetic resonance) and ITC (isothermal
titration calorimetry). Determining the actual strength of binding of the potential inhibitor
analogs compared to the existing inhibitors would be very useful to verify the results
gained from PyRx models.
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Because our current data is based on computer modeling, we suggest a next step
would be in vitro experimentation using a mast cell line to determine the efficacy of
potential inhibitors in a cellular environment. To accomplish this a MC/9 mast cell line
can be used, which are mouse liver mast cells that express FceR1 and will release
histamine when exposed to antigens after incubating with anti-Fc-receptor antibodies
(ATCC® CRL-8306™). These cells are commonly used in degranulation assays because
they can be induced into degranulation, which is the main context of measurement for
this study.
In order to measure said degranulation accurately, it will also be necessary to
collect control data of degranulation in known conditions. The first most important test
would be a negative control to determine how much histamine and other degranulatory
substances are released naturally when the cells are at rest and not being induced to
degranulate. As a positive control, degranulation can be induced using the addition of
IgE. Degranulation can be assayed using enzyme linked immunosorbent assay (ELISA)
or flow cytometry. Relative intensities of degranulation and concentrations of
degranulatory metabolites can be measured to see if relative mast cell degranulation is
lower in solutions with the inhibitor analog present compared to the existing inhibitor and
simple uninhibited mast cells. If degranulation is actually reduced with the analog
ligands, they can finally be put into testing for novel anti-allergic drugs. Following
cellular assays, future experimentation can be conducted on murine models to model the
effects of the therapeutic in a mammalian system. If time permits, future experimentation
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within murine models will be conducted in order to understand and minimize negative
effects on other bodily functions.
Another possible avenue for future research is to determine how to best target
these potential therapeutics to mast cells. One popular method of targeted drug delivery is
using nanoparticles. Currently, nanoparticles are being used to encapsulate and deliver
antigen-specific immunotherapy and DNA vaccines (Pohlit et al., 2017). Nanoparticles
confer several advantages over traditional drug delivery systems: protection against
degradation, targeted delivery, and higher concentrations at the delivery site for increased
effectiveness. These can also be biodegradable or nonbiodegradable and their surfaces
can be highly customized to target specific cells (Pohlit et al., 2017).. Nanoparticles are a
promising method of delivering our identified drug targets to mast cells to suppress
histamine release. The future direction outlined here would be crucial to further
understanding the efficacy and safety of the potential inhibitors.
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Equity Impact Report
Using the Racial Equity Impact Assessment, we assessed our research on the basis
of several factors: identifying the stakeholders in our research, examining the causes,
considering adverse impacts, and examining alternatives and improvements. This
framework was posed by race forward─the center for racial justice innovation and it
provides a guide to address questions of equity. In this report, we discuss the impact of
our research on various racial/ethnic and socioeconomic groups and provide
recommendations for equitable next steps of our research.
Defining Equity in Healthcare
Our team first defined the difference between equity and equality, as defining the
distinction between these two terms was important for our consideration of equity in our
research. Equality does not take into account disparities in need while equity does. Equity
can be thought of as synonymous with justice and it has three aims: focus, inclusion, and
narrowing gaps (World Health Organization, 2000). The focus is on the health of the
vulnerable population and thus our policy should focus on improving the health of the
most vulnerable. We should consider the inclusivity of our study to ensure that no
communities are left out. Finally, our research policy should narrow the current gaps in
health.
According to the World Health Organization (2000), equity in health is aimed to
minimize avoidable disparities in health and its determinants and to have an equitable
distribution of health care resources. In order to have equitable access, the distribution of
health services must take into account the social, economic, and demographic
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characteristics and need. Thus, to discuss equitable access to our allergy therapeutic we
must understand the needs of the demographics whom our research will impact.
Who Our Research Serves: Identifying Stakeholders
Throughout the years, the field of medicine has evolved to consider various
socioeconomic and cultural factors that shape a person’s health. Research highlights
certain groups that are more prone to allergies than others and those that struggle with
symptom management.
Susceptibility to allergies is partly based on race. A study on young children aged
1-8, including Afro-American and Caucasian children, investigated the effects of strong
risk factors of allergy, including going to daycare more often and exposure to secondhand
tobacco smoke. (Sun & Sundell, 2011). African American children of the study were
found more likely to have a positive skin prick test (diagnostic test for allergens) and
elevated allergen-specific and total IgE which mediates the allergic response. These
differences persisted even after standardizing for income, education, environmental
exposures, and many other lifestyle factors that differed between races (Wegienka et al.,
2011). Black women are also 2.5 times more likely to be sensitized to at least 3 allergens
compared to white women (Wegienka et al., 2011). It is also known that people with
multiple food allergies are at greater risk of severe food-induced reactions (Bilaver et al.,
2016). Lastly, Black children under 18 years old have double the diagnoses for allergic
disease compared to white children (Wegienka et al., 2011). Black patients are also at an
increased risk of having severe food-induced anaphylaxis (Warren et al., 2021). Asian
children have higher odds of developing food allergies compared to white children,
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whereas Hispanic children are less likely to develop food allergies than white children
(Bilaver et al., 2016). Further research needs to be conducted to determine if these
disparities are caused by genetics or lifestyle.
Among those who have allergies, socioeconomic factors affect disparities in
diagnosis, treatment, and prevention. It is known that low income children who meet the
criteria for food allergy were not diagnosed by a physician as often as high income
children (Warren et al., 2021). Population studies on families with children who have
food allergies have shown that the lowest income families spend 2.5 times more money
on emergency department visits and hospitalization (Bilaver et al., 2016). On the other
hand, families with a higher household income spent more on out-of-pocket medications
and specialist visits and that epinephrine auto-injectors, one of the primary treatments for
anaphylactic shock, has placed an economic burden on low-income families. Patients on
Medicaid receive less follow up care than patients who can afford private insurance,
which can help prevent recurrence of severe symptoms (Warren et al., 2021). This
suggests that children from families with a higher socioeconomic status are more likely to
receive adequate treatments and preventative care that lowers their risk for serious
symptoms.
It is also important to consider racial inequities in access to medical care. Some
factors include access to transportation, income, insurance coverage, and medical
trust/physician cultural competency, among others (Warren et al., 2021). For example, it’s
been shown that black children are less likely to have a food allergy diagnosis by a
physician, attesting to structural barriers to medical care (Warren et al., 2021). Overall,
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barriers faced by racial and socioeconomic minority groups need to be overcome so that
our proposed therapeutics can help treat these patient populations.
Examining the Causes of Inequities and Considering Adverse Impacts
Research that is conducted with the best intentions can often be misused for
different applications. In our study, we identified potential drug targets to be proposed to
pharmaceutical companies for further testing and drug development. Our hope is that
these medications can be distributed equitably to those with allergies. Unfortunately,
there are barriers to universal access to medication that will curtail the potential impact of
this research.
One issue that provides barriers to vulnerable populations is accessibility to the
medication. The paper Measuring Equity in Access to Pharmaceutical Services Using
Concentration Curve establishes a model to score access to pharmaceuticals. This
measure takes into account several access indicators with a score of 100 to prescriptions
that are available in any pharmacy to a score of one to prescribed medicines that are not
available at all. A score of 90 was given if a patient has to change to an alternate drug and
scores of 60 and 50 are given if patients have to make a trip to a larger city to have
availability to the drug (Davari et al., 2015).The proposed methodology then includes
scores for socioeconomic status by providing a ranking for income, occupation,
education, home status and family size. The sum of these scores is used to determine the
socioeconomic status of the individual which can be used to access the barrier they might
face to receiving pharmaceutical treatments. This study provided a method for measuring
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socioeconomic status and pharmaceutical equity. Future research into the development of
our proposed therapeutic should follow this framework to assess accessibility.
Disparities in access to medication can affect how our proposed treatments are
distributed. Areas with a high percentage of minorities have less pharmacy density and
communities with a low average income level, low employment, and high crime rates are
less likely to have access to home medication delivery services (Chisholm-Burns et al.,
2017). In addition, uninsured patients are four times more likely to not take medications
for financial reasons, and patients with lower income who have higher out of pocket
medication costs are at much greater risk of cost-related medication nonadherence
(Chisholm-Burns et al., 2017). These patients are not able to afford medications at the
inflated prices set by pharmaceutical companies. Currently, the pharmaceutical industry is
controlled by the free market, where supposedly high prices are a result of high research
and development costs (Spinello, 1992). If a company has a monopoly on a certain type
of drug, they can control the prices, and in our capitalistic society, the goal is often to
obtain higher profits at the expense of accessibility/equity in distribution (Spinello,
1992). Medication nonadherence due to financial reasons leads to poorer health and
increased hospitalizations, which are also expensive, perpetuating the cycle of inequity
(Chisholm-Burns et al., 2017).
Recommendations
Our team needs to advocate for groups that may lack access to our proposed drug
by encouraging pharmaceutical companies to be more equitable in their drug pricing
policies. This could be achieved by lobbying for more governmental regulation over the
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pharmaceutical industry (Spinello, 1992). We also can recommend that the
pharmaceutical company that produces our drug should follow the proposed methodology
of Davari et al. (2015) to ensure that the drug will be equitably distributed. This way,
treatment can go to the groups who actually require it the most and our medication will
help the most vulnerable populations and close gaps in health care
Additionally, once the drug is developed it must undergo clinical trial testing to
ensure its safety and efficiency (Mbuagbaw et al., 2017). This is another opportunity to
focus on vulnerable populations. The PROGRESS Plus acronym provides a framework to
include the determinants of health within the design of a clinical trial. It stands for Place
of residence, Race/ethnicity/culture/language, Occupation, Gender, Religion, Education,
Socio-economic status, and Social capita (Mbuagbaw et al., 2017). The rationale for
including place of reference makes the study designer consider how different areas, for
example rural versus urban may impact the study results. This will be particularly
important for us since allergies can be directly caused by environmental factors. The role
of minority groups in the trial must be considered as well as language and level of
education. The paper suggests not excluding participants based on their english skills for
example and over translations of the trial to ensure inclusivity. Additionally, gender can
be linked to inequalities as well and so clinical trial designers should consider ensuring
that recruitment efforts are identical to include various gender identities. In total, these
are a few key considerations that must be made to ensure that the clinical trial is inclusive
and thus provides evidence on the effects of a diverse population, especially those of
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vulnerable groups who are disproportionately impacted by allergies as discussed
previously in this report.
Through conducting our Gemstone research, we have been able to contribute to
the field of immunology and allergy research by identifying targets for drug development
and provided recommendations for an equitable framework for pharmaceutical
development and distribution. Through this project, we have committed to providing a
new therapeutic to those who suffer from allergies to provide a new, effective and
affordable option to patients that need it. By keeping these questions of equity at the
forefront of our research we have been able to complete a project that not only advances
scientific knowledge but also the needs of our society.
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Appendices
Appendix A - Glossary
Definitions are from Oxford Dictionary unless otherwise cited. Other definitions
originate from various sources in order to find the most concise or accurate definition of
relevant terms.
Adaptive immunity - immunity that has memory and occurs after exposure to an antigen
either from a pathogen or a vaccination (Molnar & Gair, 2013).
Agglutination - (with reference to bacteria or red blood cells) clumping together.
Allergy-specific immunotherapy (SIT) - administration of allergen extracts to achieve
clinical tolerance of allergens that cause symptoms in patients with allergic conditions
(Frew, 2010).
Anaphylactic shock - an extreme, often life-threatening allergic reaction to an antigen to
which the body has become hypersensitive.
Antibody - a blood protein produced in response to counter a specific antigen.
Antigen - a toxin or other foreign substance which induces an immune response in the
body, such as the production of antibodies.
Antigen-presenting cell (APC) - any cell that assists in the production of immune
responses by presenting antigen; especially any of several types of cell with monocytic
lineage that present antigen in association with class II MHC molecules, to helper T
lymphocytes.
B cell -  a lymphocyte not processed by the thymus gland, and responsible for producing
antibodies. Also known as B lymphocyte.
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Basophil - a basophilic white blood cell.
Corticosteroid - any of a group of steroid hormones produced in the adrenal cortex or
made synthetically. There are two kinds: glucocorticoids and mineralocorticoids. They
have various metabolic functions and some are used to treat inflammation.
Cytidine deaminase (AID) - enzyme that in humans is encoded by the CDA gene (Kuhn,
1993)
Cytokine - any of a number of substances, such as interferon, interleukin, and growth
factors, which are secreted by certain cells of the immune system and have an effect on
other cells.
Decongestant - used to relieve nasal congestion.
Degranulation - (of a cell) lose or release granules of a substance, typically as part of an
immune reaction.
ELISA (enzyme-linked immunosorbent assay) - a laboratory technique that uses
antibodies linked to enzymes to detect and measure the amount of a substance in a
solution, such as serum. The test is done using a solid surface to which the antibodies and
other molecules stick. In the final step, an enzyme reaction takes place that causes a color
change that can be read using a special machine. There are many different ways that an
enzyme-linked immunosorbent assay can be done. Enzyme-linked immunosorbent assays
may be used to help diagnose certain diseases. (“NCI Dictionary of Cancer Terms”, n.d.).
FcεR1 - the high affinity Immunoglobulin E receptor which is a tetrameric membrane
protein complex expressed on mast cells and basophils which belongs to the family of
immunoreceptors involved in antigen recognition (Type I 2018).
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Histamine - a compound which is released by cells in response to injury and in allergic
and inflammatory reactions, causing contraction of smooth muscle and dilation of
capillaries.
Humoral immune response - antibodies produced by B cells cause the destruction of
extracellular microorganisms and prevent the spread of infections (Janeway, 2001).
Immunoglobulin (IgE, IgG, IgM, IgD, IgA) - any of a class of proteins present in the
serum and cells of the immune system, which function as antibodies.
Interferon-γ (IFN-γ) - an interferon that is produced by T cells, regulates the immune
response, and in a form produced by recombinant DNA technology is used especially to
control infections due to inability of white blood cells to destroy certain bacteria and
fungi (Merriam-Webster).
Leukotriene - any of a group of biologically active compounds, originally isolated from
leukocytes. They are metabolites of arachidonic acid, containing three conjugated double
bonds.
Major histocompatibility complex (MHC) - major histocompatibility complex (MHC),
group of genes that code for proteins found on the surfaces of cells that help the immune
system recognize foreign substances. Also known as the human leukocyte antigen (HLA)
system.
Mast cell - a cell filled with basophil granules, found in numbers in connective tissue and
releasing histamine and other substances during inflammatory and allergic reactions.
Opsonization - making (a foreign cell) more susceptible to phagocytosis.
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Phagocytosis - the ingestion of bacteria or other material by phagocytes and amoeboid
protozoans.
Pharmacotherapy - medical treatment by means of drugs.
Proinflammatory - that promotes inflammation (Ex. When the lesions are traumatized,
or rubbed firmly, the cutaneous mast cells may release proinflammatory mediators,
causing edema, erythema, and even vesicle formation.) (Merriam-Webster, 2007)
Prostaglandin - any of a group of compounds with varying hormone-like effects, notably
the promotion of uterine contractions. They are cyclic fatty acids.
T cell - a lymphocyte of a type produced or processed by the thymus gland and actively
participating in the immune response.
Tyrosine - a hydrophilic amino acid which is a constituent of most proteins and is
important in the synthesis of some hormones.
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Energy (Δ G) Standard Deviation Kd
PKC-eta (η) Miltefosine -4.863636364 0.4365151252 2.70E-04
PKC-eta (η) Sotrastaurin -9.027272727 0.2453198284 2.38E-07
PKC-eta (η) Staurosporine -10.1 1.385640646 3.88E-08
PKC-eta (η) GSK-690693 -7.645454545 0.1809068067 2.45E-06
PKC-eta (η) A-674563 -7.881818182 0.376346069 1.65E-06
PKC-delta (Δ) Miltefosine -5.481818182 0.2676497032 9.50E-05
PKC-delta (Δ) Sotrastaurin -10.01818182 0.6750084175 4.46E-08
PKC-delta (Δ) Rottlerin -9.363636364 0.09244162777 1.35E-07
PKC-delta (Δ) Ingenol Mebuate -6.363636364 4.843195789 2.14E-05
PKC-theta (θ) Miltefosine -5.318181818 0.437762908 1.25E-04
PKC-theta (θ) Sotrastaurin -9.33 0.5375872022 1.43E-07
PKC-β1 Miltefosine -5.045454545 0.3559877424 1.99E-04
PKC-β1 Sotrastaurin -9.681818182 0.6997402115 7.87E-08
PKC-β1 Midostaurin -9.633333333 0.05773502692 8.54E-08
PKC-β1 Enzastaurin -10.15454545 0.3830499611 3.54E-08
PKC-β1 Ruboxistaurin -8.736363636 1.80403588 3.89E-07
PKC-β2 Miltefosine -4.818181818 0.3124681802 2.91E-04
PKC-β2 Sotrastaurin -8.981818182 0.460039524 2.57E-07
PKC-β2 Midostaurin -9.3 0.1 1.50E-07
PKC-β2 Enzastaurin -9.4 0.3130495168 1.27E-07
PKC-β2 Ruboxistaurin -9.009090909 0.1921173884 2.45E-07
PI3K Wortmannin -7.627272727 0.3608071759 2.53E-06
PI3K LY294002 -7.527272727 0.09045340337 3.00E-06
PI3K ZSTK474 -8.427272727 0.1793929156 6.55E-07
PI3K Nobiletin -6.363636364 0.1858640755 2.14E-05
PLC-γ1 GDP -7.8375 0.3020761493 1.77E-06
PLC-γ1 Resveratrol -7.590909091 0.5300085763 2.69E-06
PLC-γ1 Piceatannol -7.681818182 0.430855386 2.31E-06
PLC-γ1 U73122 -8.6 0.4546060566 4.89E-07
PLC-γ1 Nicotinamide -5.254545455 0.1213559752 1.39E-04
PLC-γ2 GDP -7.3125 0.2167124494 4.31E-06
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PLC-γ2 Resveratrol -7.236363636 0.05045249791 4.90E-06
PLC-γ2 Piceatannol -7.409090909 0.1578261414 3.66E-06
PLC-γ2 U73122 -8.209090909 0.3144981572 9.47E-07
PLC-γ2 Nicotinamide -5.2 0.04472135955 1.53E-04
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Appendix C - Structure Analysis and Comparison
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